H. Xu

Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.

C. Blackburn, A. Gould, C. Barrett, 2013, Journal of medicinal chemistry.

Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.

C. Blackburn, A. Gould, C. Barrett, 2014, Bioorganic & medicinal chemistry letters.

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.

Pooja Shah, Hua Liao, John Newcomb, 2017, Nature chemical biology.

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.

Xingyue He, M. Mizutani, T. Soucy, 2021, Journal of medicinal chemistry.